| Drug Name |
Glatiramer |
| Drug ID |
BADD_D01020 |
| Description |
Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis. |
| Indications and Usage |
For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis. |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AX13 |
| DrugBank ID |
DB05259
|
| KEGG ID |
D04318
|
| MeSH ID |
D000068717
|
| PubChem ID |
65370
|
| TTD Drug ID |
D04CRL
|
| NDC Product Code |
0378-6961; 41524-0004 |
| UNII |
U782C039QP
|
| Synonyms |
Glatiramer Acetate | Acetate, Glatiramer | Copaxone | Glatiramer | TV 5010 | 5010, TV | TV5010 | TV-5010 |
